Why is the Mesoblast (ASX:MSB) share price frozen?

The Mesobalst (ASX: MSB) share price won't be going anywhere today after the company requested a trading halt pending a capital raise.

Mesoblast Limited (ASX: MSB) shares have been halted in their tracks on Friday. On a day when it is likely fortunate to be missing the action, the Mesoblast share price won't be going anywhere after the company requested the trading halt prior to market open this morning.

Let's take a look at why the biotech company requested the pause in trading.

asx share price trading halt represented by stop sign

Image source: Getty Images

Why did Mesoblast request a trading halt?

Mesoblast shares are on hiatus today as the junior healthcare company prepares to raise capital via a private placement to a "targeted industry investor".

The Mesoblast share price is expected to remain in a trading halt until such time as the company makes a further announcement or, at the latest, Tuesday next week.

The company did not provide any insights into why it is seeking to raise capital.

Mesoblast share price soars on study results

Earlier this month, the Mesoblast share price surged after the company released promising results from a phase-3 clinical trial.

Prior to the announcement, the stem-cell research company had been conducting a six-year clinical trial on treatment to reduce lower back pain.  

According to Mesoblast, patients who had a single injection of its rexlemestrocel-L reported a reduction in their back pain. These patients, who suffered from inflammatory disc disease, reported no pain for at least two years and were compared to patients treated with a placebo.

Management has advised it intends to meet with the United States Food and Drug Administration to discuss potential approval pathways for rexlemestrocel-L.

How have Mesoblast shares been performing?

Mesoblast describes itself as a world leader in the development of regenerative medicines for inflammatory diseases. 

The company was a favourite among retail investors last year after it announced promising results for its Remestemcel-L (Ryonsil) treatment for COVID-19.

After hitting a six-year peak of $5.50 in September last year, the Mesoblast share price has more than halved. Mesoblast shares crashed from their highs late last year after the company reported a setback to its COVID-19 treatment trial.

Mesoblast cited that changes in the treatment regimens for COVID-19 patients were to blame for the trial's failure.

Shares in Mesoblast have returned to being one of the most shorted on the ASX, with an 8.8% short interest. 

The Mesoblast share price last traded at $2.46, marking a 6.5% increase for the year to date.

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ASX Share Market News

Happy wife holding her hands on her husband's shoulders while both look at a laptop.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A man stands in front of a chart with an arrow going down and slaps his forehead in frustration.
ASX Share Market News

ASX 200 mining shares smashed in major market sell-off

The ASX 200 fell 5.39% amid a mining sell-off, with BHP shares tumbling almost 13% last week.

Read more »

A woman weraing a stripy t-shirt winks as she points to the decorative gold crown on her head.
ASX Share Market News

CBA shares back on top of the ASX 200 as BHP dives 13% this week

CBA shares have rallied 9.5% over the past month whilst BHP tumbled 13% this week.

Read more »

a man wearing a hard hat and a high visibility vest stands with his arms crossed in front of heavy equipment at a mine site.
Broker Notes

BHP share price drops 13% to seven-month low in just 1 week. Do experts say buy?

Market analysts offer their advice as BHP shares plunge this week.

Read more »

A distressed young woman reads bad news on her smartphone while standing in a modern indoor setting.
Broker Notes

5 ASX 200 shares experts recommend we buy amid the market carnage this week

ASX 200 shares are down 5.2% this week and back in the red for 2026 overall.

Read more »

Comical investor reading documents and surrounded by calculators.
Broker Notes

Buy, hold, sell: Hub24, Reece, Ramsay Healthcare shares

Analysts reveal their ratings on this financial services provider, plumbing supplies company, and private hospital operator.

Read more »

IPO spelt out on a laptop with a red and green bar chart underneath.
IPOs

Anthropic hits the market. Was it enough to distract investors from a bruised AI sector and Nvidia's scandal?

Was the biggest IPO in US history enough to re-energise the AI trade?

Read more »

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward.
Broker Notes

Three of the worst performers in the ASX 200. Brokers think they're ready to bounce back

There could be a lot of value in these poor performers.

Read more »